NCT06778850

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

A Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MDR-001 Tablets Administrated Orally in Healthy Participants and Obese/ Overweight Participants

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 131 (estimated)
• Sponsor: MindRank AI Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.

Conditions

• Overweight and Obese Volunteers

Interventions

Type	Name	Description
DRUG	MDR-001	Oral administration of small molecule MDR-001 tablets
DRUG	palcebo	Administered orally placebo

Timeline

• Start date: 2023-06-09
• Primary completion: 2025-07-15
• Completion: 2025-12-30
• First posted: 2025-01-16
• Last updated: 2025-03-07

Locations

1 site across 1 country: China